ARX-04: Ph III SAP303 data

The open-label, U.S. Phase III SAP303 in 140 patients ages ≥40 who have undergone a surgical procedure with general or spinal anesthesia showed that 30 ug sublingual ARX-04 every hour as needed for pain management for up to 12 hours reduced mean pain intensity from baseline during the first 2 hours by 49%. AcelRx said pain relief was reported as early as 15 minutes after the start of dosing, with the "majority" of patients experiencing an overall reduction in pain level from "high moderate" at baseline to "mild" by 2 hours...